Juno Therapeutics Could Nearly Double On Data, Multiple Catalysts, Says FBR Analyst

By: via Benzinga
In a report published Tuesday, FBR analyst Ed White initiated coverage of Juno Therapeutics Inc (NASDAQ: JUNO) with an Outperform rating ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.